The expansion of clinical trial sites for Genprex's Acclaim-3 study is a positive development, indicating progress in the clinical trial process. The support from the FDA through Orphan Drug and Fast Track Designations underscores the potential of Reqorsa Therapy in combination with Tecentriq. This news is likely to be viewed positively by investors, as it demonstrates Genprex's commitment to advancing its pipeline and could potentially speed up the time to market for Reqorsa Therapy.